SR7826 (10 mg/kg; oral gavage; once daily; for 11 days; hAPPJ20 mice) treatment significantly reduces the phosphorylation of cofilin at Ser3. SR7826 also increases both apical and basal thin spine density significantly in hAPPJ20 mice over mock-treated animals[2].
The plasma pharmacokinetics studies on rats are investigated. After intravenous injection, the PK properties of SR7826 (compound 18b; 1mg/kg) with a Cl of 5.2 mL/min/kg, a T1/2 of 2.2h, an AUC of 8.4 μM*h and a Cmax of 7.7 μM, and has 36% oral bioavailability in rats (oral administration; 2mg/kg)[1].
| Animal Model: | hAPPJ20 mice (6-mouth-old)[2] |
| Dosage: | 10 mg/kg |
| Administration: | Oral gavage; once daily; for 11 days |
| Result: | Significantly reduced the phosphorylation of cofilin at Ser3, a LIMK1 substrate.
|